Allogeneic Hsct
Allogeneic Hsct - Related Videos
06:48
Transplantation of Tail Skin to Study Allogeneic CD4 T Cell Responses in Mice
0 Views •
Cited by 10 •
2014
Tail-skin transplantation is a powerful model for studying T cell-dependent rejection and tolerance induction during allogeneic immune responses in mice. The advantages of this protocol are minor invasive surgery, and ease of monitoring with no need to sacrifice the recipient mouse.
08:52
Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
0 Views •
Cited by 49 •
2011
A rapid, simple and cost-effective protocol for the generation of donor-derived multivirus-specific CTLs (rCTL) for infusion to allogeneic hematopoietic stem cell transplant (HSCT) recipients at risk of developing CMV, Adv or EBV infections. This manufacturing process is GMP-compliant and should ensure the broader implementation of T-cell immunotherapy beyond specialized centers.
09:01
A Quantitative Assessment of the Phagocytosis of Allogeneic and Xenogeneic Erythrocytes by Rat Macrophages In Vitro
0 Views •
2025
This work describes a standardized in vitro protocol to quantify and compare the phagocytosis rates of xenogeneic (human) and allogeneic (rat) red blood cells by isolated rat macrophages.
05:54
Induction of Graft Versus Host Disease in Mouse Models via Allogeneic Bone Marrow and Splenic Cell Transplantation
0 Views •
2025
This video demonstrates the induction of intestinal graft-versus-host disease, GvHD, in a lethally-irradiated recipient mouse using allogeneic hematopoietic stem cells and GvHD-inducing splenic alloreactive T lymphocytes. This protocol helps establish a severe acute intestinal GvHD model to understand the mechanism of the disease and develop innovative therapeutic options.
11:22
Treatment of Osteochondral Defects in the Rabbit's Knee Joint by Implantation of Allogeneic Mesenchymal Stem Cells in Fibrin Clots
0 Views •
Cited by 32 •
2013
An experimental technique for the treatment of osteochondral defects in the rabbit's knee joint is described. The implantation of allogeneic mesenchymal stem cells into osteochondral defects provides a promising development in the field of tissue engineering. The preparation of fibrin-cell-clots in vitro offers a standardized method for implantation.
FAQs
Donor T cells can recognize and attack residual malignant cells after transplantation, producing the graft-versus-leukemia effect. This immune activity provides an additional antitumor mechanism beyond conditioning therapy and donor-cell engraftment. However, allo-HSCT also requires attention to graft-versus-host disease, illustrating the need to balance beneficial donor immune responses with harmful immune reactions.
Conditioning therapy suppresses the recipient’s bone marrow and immune system before donor-cell infusion. This prepares the recipient for replacement of blood-forming stem cells and supports subsequent donor-cell engraftment. Because conditioning directly affects marrow and immune function, it also forms part of the biological context for later blood-cell recovery, immune reconstitution, and infection susceptibility.
Histocompatibility helps determine whether donor and recipient tissues are genetically compatible enough for transplantation. The overview identifies donor selection as a central immunology issue because compatibility affects the interaction between donor cells and the recipient after infusion. Investigators and clinicians therefore consider this relationship when planning transplantation and evaluating risks such as graft-versus-host disease.
Following engraftment, donor stem cells reconstitute blood and immune cell production in the recipient. This process makes allo-HSCT a useful model for studying immune reconstitution, including how immune function returns after conditioning and transplantation. Recovery is not equivalent to immediate normal immunity, since the post-transplant period remains associated with susceptibility to opportunistic infections and requires continued monitoring.
A typical pathway begins with donor selection and conditioning therapy, followed by infusion of genetically compatible donor stem cells. Clinicians then assess engraftment, blood and immune cell recovery, graft-versus-host disease, and possible infections. Post-transplant care includes monitoring and prophylaxis, allowing teams to respond to immune complications while tracking the restoration of hematopoietic function.
Allo-HSCT creates a setting in which marrow suppression, immune reconstitution, and donor-recipient immune interactions can be studied together. Patients may become susceptible to opportunistic infections during immune recovery, making prophylaxis and monitoring important components of care. The transplant therefore connects immunology with infection research while informing management of hematologic cancers, marrow failure, and selected immune disorders.